Heart Rhythm

Hearts should have normal rhythm to their beats, but when these beats are out of synch, it causes inefficient pumping of blood. Irregular heart arrhythmias occur when the electrical signals that coordinate the heart's beats do not work properly. This can cause beats that are too fast (tachycardia), or too slow (bradycardia). Tachycardias include atrial fibrillation (AFib), supraventricular tachycardia, ventricular fibrillation, and ventricular tachycardia (VT). Bradycardias include sick sinus syndrome and conduction block. Electrophysiology arrhythmia treatments include medications, life style changes, and the EP lab interventions of catheter ablation, and implantable pacemakers or defibrillators.

RSS icon

Rivaroxaban appears safe, effective for elderly patients

Elderly patients in ROCKET AF saw equal benefits with less risk of intracranial bleeding with rivaroxaban compared with warfarin. But there was a greater risk of noncranial bleeding in these patients.

Medtronic launches Advisa and Ensura SR MRI SureScan pacemaker Systems in Europe

Medtronic, Inc. (NYSE: MDT), today announced CE (Conformité Européenne) Mark and commercial launch of the Advisa and Ensura SR MRI(tm) SureScan single chamber pacemaker devices in Europe. Both pacemakers are approved for magnetic resonance imaging (MRI) scans positioned on any region of the body. These devices are not approved in the United States.

eCardio and Yocaly will jointly advance remote cardiac monitoring in the United States

eCardio Diagnostics, LLC (eCardio), a leader in remote cardiac arrhythmia monitoring services in the United States, and Shandong Yocaly Information Science & Technology Co., Ltd. (Yocaly), a remote, real-time medical cardiac monitoring solution provider headquartered in Jinan, China, have recently signed a strategic cooperation agreement focused on furthering the advancement of remote cardiac monitoring products and services in the United States, China and beyond.

Thumbnail

Medtronic pays $9.9M to settle kickback claims

Medtronic has agreed to pay nearly $10 million to settle a whistleblower case over alleged kickbacks to physicians who treated patients with its pacemakers and defibrillators.

Thumbnail

Boehringer earmarks $650M to settle Pradaxa suits

Boehringer Ingelheim will pay $650 million in a comprehensive settlement over its anticoagulant dabigatran. The company faced thousands of lawsuits in the U.S. from patients who claimed the drug caused severe and fatal bleeding.

FDA study weighs in favor of dabigatran

The FDA maintained its position on the safety of the anticoagulant dabigatran after completing a study that included an older patient population. Based on the results, the agency said it would make no changes in its recommendations or to the labeling.

Feds scrutinizing two cardiac device makers

Two manufacturers are under the federal magnifying glass with investigations involving implantable cardiac devices. The investigations are unrelated.

HRS.14: ACE inhibitors, ARBs lower incidence of appropriate shocks

ACE inhibitors and ARBs have a protective effect on patients with cardiomyopathy who receive implantable cardioverter-defibrillators (ICDs), according to an analysis presented May 8 at the Heart Rhythm Society scientific session in San Francisco.

Displaying 1073 - 1080 of 1668

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup